Trials / Conditions / ALK Gene Rearrangement Positive
ALK Gene Rearrangement Positive
6 registered clinical trials studyying ALK Gene Rearrangement Positive — 1 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Unknown | Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC NCT04989322 | Dr Joanne CHIU | Phase 2 |
| Recruiting | Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLC NCT05122806 | Groupe Francais De Pneumo-Cancerologie | N/A |
| Completed | Alectinib in Combination With Bevacizumab in ALK Positive NSCLC NCT03779191 | Instituto Nacional de Cancerologia de Mexico | Phase 2 |
| Completed | A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squam NCT04042558 | Centre Francois Baclesse | Phase 2 |
| Completed | Efficacy of Treatment Sequences in Patients With Non-small Cell Lung Cancer Receiving Lorlatinib NCT03727477 | Intergroupe Francophone de Cancerologie Thoracique | — |
| Available | Expanded Access to Ensartinib for Participants With ALK+ NSCLC NCT04146571 | Xcovery Holdings, Inc. | — |